Hopstem Biotechnology announced that first subject of the registered clinical trial of hNPC01 Injection has completed the administration. As the sponsor-initiated Phase I registered clinical trial has been successfully conducted by Professor Zhiquan Yang and his team at Xiangya Hospital, the first subject received the initial dose of hNPC01 Injection on December 7 and has remained stable with normal indicators, experiencing no complications related to the surgery or perioperative period. The subject was discharged smoothly after three days post-surgery and continued with rehabilitation exercises.

Prof. Zhiquan Yang from Xiangya Hospital said: “The administration of the first subject in this clinical trial has been successfully completed, and after three weeks, the subject's condition is good, with preliminary evidence of muscle strength improvement. We will continue to monitor the subject's progress according to the requirements of the clinical trial protocol"

“We are grateful for the trust and support of the clinical volunteers. The significant number of stroke hemiplegia patients and their strong willingness to receive treatment are evident from the enrollment applications and screening process. The company is confident in achieving the planned completion of all dose groups' enrollment and administration. Through the efforts of internal and external partners, Hopstem Biotechnology will continue to drive high-quality, preliminary safety clinical research on ischemic stroke with strong execution to provide truly safe, effective, and affordable treatments for patients with chronic ischemic stroke.” Said  by Dr. Jing Fan, the CEO of Hopstem Biotechnology.